COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States by Bhupinder Kaur, Yee Hui Yeo, Jeff Liang, Michael Luu, Walid Ayoub, Alexander Kuo, Hirsh Trivedi, Kamya Sankar, Jun Gong, Andrew Hendifar, Arsen Osipov, Kambiz Kosari, Nicholas Nissen, Mazen Noureddin, Amit G. Singal, Ju Dong Yang

“…The distribution of cancer stage and treatment modality were assessed. Results: The pandemic led to a significant reduction in reported HCC cases, from 19,597 in 2019 to 16,188 in 2020. …”
Get full text

A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC by Roniel Cabrera, Amit G. Singal, Massimo Colombo, R. Kate Kelley, Hannah Lee, Andrea R. Mospan, Tim Meyer, Pippa Newell, Neehar D. Parikh, Bruno Sangro, K. Rajender Reddy, Stephanie Watkins, Richard C. Zink, Adrian M. Di Bisceglie

“…Most included patients were diagnosed at an early stage (Barcelona Clinic Liver Cancer Stage [BCLC] 0/A), but only approximately one third underwent curative treatment. …”
Get full text

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice by Amit G. Singal, Saurabh P. Nagar, Abby Hitchens, Keith L. Davis, Shrividya Iyer

“…Most patients had Barcelona Clinic Liver Cancer stage B (23.8%) or C (38.4%) uHCC. Median duration of lenvatinib treatment was 6.9 months, with 42.7% of patients still on treatment at the end of follow‐up. …”
Get full text